Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
3.350
-0.070 (-2.05%)
At close: Oct 30, 2026, 4:00 PM EDT
3.449
+0.099 (2.96%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Verrica Pharmaceuticals Revenue
Verrica Pharmaceuticals had revenue of $5.86M in the quarter ending June 30, 2026, a decrease of -53.85%. This brings the company's total for the last twelve months to $30.32M, up 106.21% year-over-year. In the year 2025, Verrica Pharmaceuticals had annual revenue of $35.58M with 370.22% growth. That makes Verrica Pharmaceuticals the 31,297th largest company in the world by revenue and 4,138th in the United States.
Revenue (ttm)
$30.32M
Revenue Growth
+106.21%
P/S Ratio
1.90
Revenue / Employee
$398,961
Employees
76
Market Cap
57.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.58M | 28.01M | 370.22% |
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 151.18M |
| Pelthos Therapeutics | 43.30M |
| MindWalk Holdings | 11.57M |
| Hyperion DeFi | 1.40M |
| Clene | 197.00K |
VRCA News
- 9 days ago - Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals to present new YCANTH data at upcoming conferences - TheFly
- 4 weeks ago - Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences - GlobeNewsWire
- 5 weeks ago - Verrica Pharmaceuticals management to meet virtually with Lake Street - TheFly
- 6 weeks ago - Verrica Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - Verrica Pharmaceuticals Slides: Corporate presentation - Filings
- 7 weeks ago - Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences - GlobeNewsWire
- 7 weeks ago - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire